Additional Relevant Details The study demonstrated that the range of responses to MBX-8025 was broad, but that MBX-8025 provided a clinically meaningful reduction in low-density lipoprotein cholesterol (LDL-C) for a subset of patients.  The average maximum decrease in the study was 19% of LDL-C (low-density lipoprotein cholesterol).  The overall mean change for all 12 subjects was a decrease of 10%.